ACS's goal is to survey 100,000 Black women between ages 25 and 55 who have not had a cancer diagnosis across the U.S. to increase understanding of Black women's health amid sharp racial health ...

East Harris County has elevated levels of cervix uteri, leukemia, lung and bronchus, and lymphoma cancers, the Texas ...

Laura Wharam thought she had appendicitis but her breast cancer had returned and metastasized, spreading to her liver, bones, ...

Higher TIL levels predict better survival in early ERBB2-positive breast cancer, supporting treatment de-escalation for select patients.

More widespread use of mammograms, along with the implementation of targeted hormone therapies more than 40 years ago, has ...

Lack of screening and limited treatment options mean that low- and middle-income countries face higher death rates despite ...

After battling cancer and learning about harmful ingredients, Emily Phillips, 35, changed her diet completely. But what do oncology experts think?

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

India's pharmaceutical market is witnessing a surge in new drug launches, particularly in the oncology segment, fueled by a ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.